CA3113968C - 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds - Google Patents

6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds Download PDF

Info

Publication number
CA3113968C
CA3113968C CA3113968A CA3113968A CA3113968C CA 3113968 C CA3113968 C CA 3113968C CA 3113968 A CA3113968 A CA 3113968A CA 3113968 A CA3113968 A CA 3113968A CA 3113968 C CA3113968 C CA 3113968C
Authority
CA
Canada
Prior art keywords
mmol
pharmaceutically acceptable
acceptable salt
stirred
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3113968A
Other languages
English (en)
French (fr)
Other versions
CA3113968A1 (en
Inventor
Nicolas Jacques Francois Dreyfus
Jose Eduardo Lopez
Leonard Larry Winneroski, Jr.
Eric Michael Woerly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3113968A1 publication Critical patent/CA3113968A1/en
Application granted granted Critical
Publication of CA3113968C publication Critical patent/CA3113968C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA3113968A 2018-09-26 2019-09-19 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds Active CA3113968C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736588P 2018-09-26 2018-09-26
US62/736,588 2018-09-26
PCT/US2019/051820 WO2020068530A1 (en) 2018-09-26 2019-09-19 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds

Publications (2)

Publication Number Publication Date
CA3113968A1 CA3113968A1 (en) 2020-04-02
CA3113968C true CA3113968C (en) 2023-08-01

Family

ID=68085016

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3113968A Active CA3113968C (en) 2018-09-26 2019-09-19 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds

Country Status (8)

Country Link
US (2) US10752632B2 (https=)
EP (1) EP3856739A1 (https=)
JP (2) JP7081047B2 (https=)
CN (1) CN112955446B (https=)
AR (1) AR116428A1 (https=)
CA (1) CA3113968C (https=)
TW (1) TWI716107B (https=)
WO (1) WO2020068530A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI716107B (zh) * 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
US20240043418A1 (en) * 2020-03-26 2024-02-08 Richter Gedeon Nyrt. 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
WO2024081775A1 (en) 2022-10-14 2024-04-18 Eli Lilly And Company Synthesis of 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8726763D0 (en) 1987-11-16 1987-12-23 Fujisawa Pharmaceutical Co Thiazole compounds
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
RS58768B1 (sr) 2013-03-14 2019-06-28 Merck Patent Gmbh Inhibitori glikozidaze
KR102043337B1 (ko) * 2014-08-28 2019-11-11 아셰뉴론 에스아 글리코시다제 저해제
CN107428762B (zh) 2015-10-30 2020-03-10 四川科伦博泰生物医药股份有限公司 酞嗪酮衍生物、其制备方法及用途
EP3389658B1 (en) 2015-12-18 2020-11-25 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
FR3046053B1 (fr) 2015-12-24 2017-12-22 Sagem Defense Securite Module de pied pour une structure d'exosquelette
KR20180132629A (ko) * 2016-02-25 2018-12-12 아셰뉴론 에스아 글리코시다제 저해제
CA3045957A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds
US20190359609A1 (en) * 2016-12-16 2019-11-28 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
TWI669302B (zh) 2017-05-25 2019-08-21 美商美國禮來大藥廠 5-甲基-1,3,4-<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>二唑-2-基化合物
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物

Also Published As

Publication number Publication date
JP2022116171A (ja) 2022-08-09
JP7081047B2 (ja) 2022-06-06
US20200354370A1 (en) 2020-11-12
TWI716107B (zh) 2021-01-11
US20200095254A1 (en) 2020-03-26
CN112955446A (zh) 2021-06-11
JP2022502389A (ja) 2022-01-11
EP3856739A1 (en) 2021-08-04
JP7560511B2 (ja) 2024-10-02
CN112955446B (zh) 2024-07-12
AR116428A1 (es) 2021-05-05
WO2020068530A1 (en) 2020-04-02
US10752632B2 (en) 2020-08-25
CA3113968A1 (en) 2020-04-02
US10836773B1 (en) 2020-11-17
TW202026293A (zh) 2020-07-16

Similar Documents

Publication Publication Date Title
US10081625B2 (en) 5-methyl-1,2,4-oxadiazol-3-yl compounds
JP6294918B2 (ja) 選択的ＮＫ−３受容体拮抗薬としての新規なキラルＮ−アシル−５，６，７，（８位置換）−テトラヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法およびキラル合成
JP5481008B2 (ja) テトラヒドロ・イミダゾ［１，５−α］ピラジン誘導体、その調製プロセスおよび医薬的使用
JP7560511B2 (ja) ６－フルオロ－２－メチルベンゾ［ｄ］チアゾール－５－イル化合物
AU2014281032A1 (en) Bace inhibitors
CA3056027A1 (en) Cyclic substituted imidazo[4,5-c]quinoline derivatives
WO2019156861A1 (en) [1,2,4]triazolo[4,3-a]pyrazin-8-one derivatives
CA3108158C (en) 5-methyl-4-fluoro-thiazol-2-yl compounds
HK40009770A (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
HK1134817B (en) Tetrahydro-imidazo[1,5-a]pyrazine derivatives, preparation methods and medical uses thereof
NO330342B1 (no) Ny fremgangsmate for fremstilling av imidazolylforbindelser

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210323

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241218

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241218

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905